Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.58 |
| ▸ | HSF1 | Q00613 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CDK4 | P11802 | 12/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374455 | 0.87 | SRC (0.61) | CDK2CCNE1HSF1MEN1KMT2A | |
| SCHEMBL1387593 | 0.84 | CDK2 (0.56) | CDK2CCNE1HSF1MEN1KMT2A | |
| SCHEMBL12517808 | 0.80 | TNNI3K (0.72) | EGFR | |
| SCHEMBL12485614 | 0.78 | MEN1 (0.87) | MEN1KMT2ACDK4NPC1RAB9A | |
| SCHEMBL1387382 | 0.78 | MEN1 (0.52) | CDK2CCNE1HSF1MEN1KMT2A | |
| SCHEMBL1640720 | 0.77 | HRH3 (0.59) | — | |
| SCHEMBL374814 | 0.77 | CYP3A4 (0.53) | MEN1KMT2ASRCKDREPHB4 | |
| SCHEMBL374753 | 0.76 | SRC (0.50) | MEN1KMT2ANPC1RAB9AABL1 | |
| SCHEMBL4768749 | 0.76 | MEN1 (0.59) | MEN1KMT2ACDK4NPC1RAB9A | |
| SCHEMBL374272 | 0.75 | SRC (0.51) | MEN1KMT2ANPC1RAB9AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976847-B1 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8759517-B2 | Pyrirnidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8293746-B2 | Pyrimidinyl aryl urea derivatives being FGF inhibitors | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| EP-1976847-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | Novartis AG (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007071752-A2 | PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | CDK2 24/4885CCNE1 454/4885HSF1 1199/4885 |
| US-20130030171-A1 | Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors | FGFR1, FGF1, FGF2 | CDK2 24/4885CCNE1 454/4885HSF1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.